We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Variants Predict Child Neuroblastoma Risk

By LabMedica International staff writers
Posted on 02 Oct 2017
Potential biomarkers predicting a child's risk for developing neuroblastoma are linked to common variants in the MMP20 (matrix metalloproteinase-20) gene on chromosome 11q.

Investigators at Children's Hospital of Philadelphia (PA, USA) used a genome-wide association study (GWAS) to identify common variants at chromosome locus 11q22.2 within MMP20 that associated with neuroblastoma cases harboring an 11q deletion in 113 European-American cases and 5109 ancestry-matched controls. More...
The association was replicated in 44 independent cases and 1902 controls.

"These inherited variants predispose to 11q deletions, which are a strong risk factor," said Dr. Hakon Hakonarson, director of the center for applied genomics at Children's Hospital of Philadelphia.

"We already knew that 11q deletions are biomarkers that predict poor outcomes in neuroblastoma," said contributing author Dr. John M. Maris, pediatric oncologist at Children's Hospital of Philadelphia. "This new research helps us to more precisely predict how a neuroblastoma tumor will behave, so it improves our diagnostic capabilities."

The study was published in the September 18, 2017, online edition of the journal Nature Communications.

Related Links:
Children's Hospital of Philadelphia


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.